Menu
Medicines at
the Nexus of
Metabolism &
Immunity
"Path to End Patient Suffering"
Nirogy Story & Vision
“Nirogy” means “without illness” in Sanskrit. Our vision is to create a path to end patient suffering. Nirogy has been trying to unravel the intricate symbiotic communication network among various cell types in the tumor and immune microenvironment (TIME)…
Nirogy Story & Vision
“Nirogy” means “without illness” in Sanskrit. Our vision is to create a path to end patient suffering. Nirogy has been trying to unravel the intricate symbiotic communication network among various cell types in the tumor and immune microenvironment (TIME)…
Transformative Science
A pioneer in the metabolic solute carrier transporter (SLCT) space, a largely untapped target class, for hard-to-treat diseases such as cancer, autoimmunity, and inflammation…
Passionate Team
An experienced team of science, business, and operations united by a common goal…
Nirogy News
Nirogy Therapeutics Launches with $16.5 Million Series A Financing
Proceeds to support the development of small-molecule drugs that modulate the transport of metabolites for oncology and immunology indications Boston, January 26, 2021 – Nirogy Therapeutics Inc., a privately-held biotechnology …
Nirogy Therapeutics is Awarded $2 Million NIH/NCI SBIR Grant to Develop dMCTi for TNBC
Natick, Mass., September 25, 2020 – Nirogy Therapeutics Inc. today announced that it was awarded a $2M NIH/NCI SBIR grant to develop dual monocarboxylate transport inhibitors (dMCTi) for Triple Negative Breast …
